As of 2026-03-24, the EV/EBITDA ratio of Kymera Therapeutics Inc (KYMR) is -17.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KYMR's latest enterprise value is 5,929.28 mil USD. KYMR's TTM EBITDA according to its financial statements is -337.23 mil USD. Dividing these 2 quantities gives us the above KYMR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 15.6x | 13.8x |
| Forward P/E multiples | 14.5x - 20.8x | 18.0x |
| Fair Price | (55.73) - (60.19) | (61.35) |
| Upside | -172.4% - -178.2% | -179.7% |
| Date | EV/EBITDA |
| 2026-03-16 | -18.22 |
| 2026-03-13 | -18.08 |
| 2026-03-12 | -17.71 |
| 2026-03-11 | -18.69 |
| 2026-03-10 | -19.43 |
| 2026-03-09 | -19.54 |
| 2026-03-06 | -19.16 |
| 2026-03-05 | -19.17 |
| 2026-03-04 | -19.80 |
| 2026-03-03 | -19.86 |
| 2026-03-02 | -20.76 |
| 2026-02-27 | -21.07 |
| 2026-02-26 | -21.96 |
| 2026-02-25 | -20.90 |
| 2026-02-24 | -20.98 |
| 2026-02-23 | -20.36 |
| 2026-02-20 | -20.11 |
| 2026-02-19 | -19.89 |
| 2026-02-18 | -19.56 |
| 2026-02-17 | -19.49 |
| 2026-02-13 | -18.88 |
| 2026-02-12 | -19.29 |
| 2026-02-11 | -18.87 |
| 2026-02-10 | -18.19 |
| 2026-02-09 | -18.08 |
| 2026-02-06 | -18.22 |
| 2026-02-05 | -17.34 |
| 2026-02-04 | -17.76 |
| 2026-02-03 | -17.65 |
| 2026-02-02 | -17.26 |
| 2026-01-30 | -16.55 |
| 2026-01-29 | -16.84 |
| 2026-01-28 | -16.18 |
| 2026-01-27 | -16.42 |
| 2026-01-26 | -16.15 |
| 2026-01-23 | -15.88 |
| 2026-01-22 | -16.57 |
| 2026-01-21 | -16.08 |
| 2026-01-20 | -15.45 |
| 2026-01-16 | -15.79 |
| 2026-01-15 | -16.17 |
| 2026-01-14 | -17.16 |
| 2026-01-13 | -16.90 |
| 2026-01-12 | -16.65 |
| 2026-01-09 | -17.05 |
| 2026-01-08 | -17.10 |
| 2026-01-07 | -17.52 |
| 2026-01-06 | -16.73 |
| 2026-01-05 | -16.48 |
| 2026-01-02 | -16.57 |